Trump's Opioid Commission Asks FDA To Boost Post-Market Vigilance
Pharma is criticized for aggressive marketing, but the report also seeks industry help in research on innovative medication.
You may also be interested in...
Once the National Academies of Sciences, Engineering and Medicine find conditions needing more evidence to support prescribing guidelines, the agency may have find a way to gather the data.
Administration also plans to roll out slate of proposals to decrease drug prices and bring discounts to patients.
Pharma firms might avoid paying for national opioid prescription monitoring database because state systems already talk to each other, although current operations still need some upgrades.